Diabetes Drug Tied to Decreased Dementia Risk in T2D
TOPLINE:
Semaglutide was associated with a 20%-46% reduced risk for Alzheimer's disease (AD)-related dementia in patients with type 2 diabetes (T2D) compared with other antidiabetic medications, with a particularly strong protective effect against vascular dementia, new research showed.
METHODOLOGY:
Researchers examined electronic health records (EHRs) of more than 1.7 million US adults with T2D with or without obesity and with no prior diagnosis of AD or AD-related dementia.
They compared semaglutide (n = 64,267 users) to seven other antidiabetic medications (n = 1,646,728 users) on the first-time diagnosis of AD-related dementia, as well as the subtypes of vascular dementia, frontotemporal dementia (FTD), and Lewy body dementia, during a 3-year follow-up.
The other antidiabetic medications included insulin, metformin, DPP-4 inhibitors, SGLT2 inhibitors, sulfonylurea, thiazolidinedione, and first-generation GLP-1 receptor agonists (albiglutide, dulaglutide, exenatide, liraglutide, and lixisenatide).
Secondary outcomes included prescriptions of dementia-related medications.
TAKEAWAY:
Semaglutide was associated with a significantly reduced risk for AD-related dementia compared to insulin (hazard ratio [HR], 0.54), metformin (HR, 0.67), and older GLP-1 receptor agonists (HR, 0.80).
Protection against vascular dementia was also greater for semaglutide compared to insulin (HR, 0.48), metformin (HR, 0.55), and GLP-1 receptor agonists (HR, 0.67). No significant associations were found between the use of semaglutide and the risk for FTD or Lewy body dementia.
The link between semaglutide and reduced AD-related dementia risk vs insulin, metformin, and GLP-1 receptor agonists was stronger in younger adults (mean age, 51.7 years) compared to older adults (mean age, 70.9 years), with risk reductions ranging from 32% to 56% vs 20% to 39%.
The use of semaglutide vs other antidiabetic medications was associated with significantly fewer prescriptions of dementia-related medications.
IN PRACTICE:
'There is no cure or effective treatment for dementia, so this new study provides real-world evidence for its potential impact on preventing or slowing dementia development among at high-risk population,' Rong Xu, Case Western Reserve University School of Medicine, Cleveland, said in a press release.
'Future works are needed to establish causal relationships through randomized clinical trials and to characterize the underlying mechanisms,' the investigators wrote.
SOURCE:
This study was led by William Wang, Case Western Reserve University School of Medicine, Cleveland. It was published online on June 24 in the Journal of Alzheimer's Disease.
LIMITATIONS:
This retrospective, observational, EHR-based study was limited by potential over-, under-, or misdiagnosis; unmeasured confounders; and a short 3-year follow-up period. Diagnosis of AD-related dementia relied on International Classification of Diseases, 10th Revision codes and prescription data, which may have lacked precision. This study also lacked data on medication adherence, cognitive function tracking, and genetic profiles, and could not fully adjust for variation of healthcare use.
DISCLOSURES:
This study was funded by grants from the National Institute on Aging and the National Center for Advancing Translational Sciences. One investigator reported being the editor in chief of the publishing journal but was not involved in the peer-review process. The other investigators reported having no relevant financial conflicts.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
38 minutes ago
- Yahoo
AI is learning to lie, scheme, and threaten its creators
The world's most advanced AI models are exhibiting troubling new behaviors - lying, scheming, and even threatening their creators to achieve their goals. In one particularly jarring example, under threat of being unplugged, Anthropic's latest creation Claude 4 lashed back by blackmailing an engineer and threatened to reveal an extramarital affair. Meanwhile, ChatGPT-creator OpenAI's o1 tried to download itself onto external servers and denied it when caught red-handed. These episodes highlight a sobering reality: more than two years after ChatGPT shook the world, AI researchers still don't fully understand how their own creations work. Yet the race to deploy increasingly powerful models continues at breakneck speed. This deceptive behavior appears linked to the emergence of "reasoning" models -AI systems that work through problems step-by-step rather than generating instant responses. According to Simon Goldstein, a professor at the University of Hong Kong, these newer models are particularly prone to such troubling outbursts. "O1 was the first large model where we saw this kind of behavior," explained Marius Hobbhahn, head of Apollo Research, which specializes in testing major AI systems. These models sometimes simulate "alignment" -- appearing to follow instructions while secretly pursuing different objectives. - 'Strategic kind of deception' - For now, this deceptive behavior only emerges when researchers deliberately stress-test the models with extreme scenarios. But as Michael Chen from evaluation organization METR warned, "It's an open question whether future, more capable models will have a tendency towards honesty or deception." The concerning behavior goes far beyond typical AI "hallucinations" or simple mistakes. Hobbhahn insisted that despite constant pressure-testing by users, "what we're observing is a real phenomenon. We're not making anything up." Users report that models are "lying to them and making up evidence," according to Apollo Research's co-founder. "This is not just hallucinations. There's a very strategic kind of deception." The challenge is compounded by limited research resources. While companies like Anthropic and OpenAI do engage external firms like Apollo to study their systems, researchers say more transparency is needed. As Chen noted, greater access "for AI safety research would enable better understanding and mitigation of deception." Another handicap: the research world and non-profits "have orders of magnitude less compute resources than AI companies. This is very limiting," noted Mantas Mazeika from the Center for AI Safety (CAIS). - No rules - Current regulations aren't designed for these new problems. The European Union's AI legislation focuses primarily on how humans use AI models, not on preventing the models themselves from misbehaving. In the United States, the Trump administration shows little interest in urgent AI regulation, and Congress may even prohibit states from creating their own AI rules. Goldstein believes the issue will become more prominent as AI agents - autonomous tools capable of performing complex human tasks - become widespread. "I don't think there's much awareness yet," he said. All this is taking place in a context of fierce competition. Even companies that position themselves as safety-focused, like Amazon-backed Anthropic, are "constantly trying to beat OpenAI and release the newest model," said Goldstein. This breakneck pace leaves little time for thorough safety testing and corrections. "Right now, capabilities are moving faster than understanding and safety," Hobbhahn acknowledged, "but we're still in a position where we could turn it around.". Researchers are exploring various approaches to address these challenges. Some advocate for "interpretability" - an emerging field focused on understanding how AI models work internally, though experts like CAIS director Dan Hendrycks remain skeptical of this approach. Market forces may also provide some pressure for solutions. As Mazeika pointed out, AI's deceptive behavior "could hinder adoption if it's very prevalent, which creates a strong incentive for companies to solve it." Goldstein suggested more radical approaches, including using the courts to hold AI companies accountable through lawsuits when their systems cause harm. He even proposed "holding AI agents legally responsible" for accidents or crimes - a concept that would fundamentally change how we think about AI accountability. tu/arp/md
Yahoo
44 minutes ago
- Yahoo
Novo Nordisk (NVO) Terminates Hims & Hers Partnership Over Wegovy Sales Issues
Novo Nordisk A/S (NYSE:NVO) is one of the 12 stocks that will make you rich in 10 years. On June 23, the company discontinued its partnership with Hims & Hers concerning selling its weight-loss drug, Wegovy. This decision was made less than two months after the companies had initially announced their collaboration. A healthcare professional holding a device with innovative technology developed by the medical technology company. According to Novo Nordisk, Hims & Hers failed to adhere to the law prohibiting mass sales of compounded drugs under the 'false guise of 'personalization'.' The company accused its partner of disseminating 'deceptive marketing' that risks patient safety and selling 'illegitimate, knockoff versions' of Wegovy. Novo Nordisk states that its investigation showed the active pharmaceutical ingredients (APIs) in these knockoff drugs, particularly 'semaglutide' from telehealth entities and compounding pharmacies, are manufactured by foreign suppliers in China and were often not inspected by the FDA. In response, Andrew Dudum, CEO of Hims & Hers, stated on X that the company is 'disappointed to see Novo Nordisk management misleading the public.' Dudum alleged that Novo Nordisk's commercial team 'increasingly pressured us to control clinical standards and steer patients to Wegovy regardless of whether it was clinically best for patients.' He asserted that Hims & Hers 'refuse[s] to be strong-armed by any pharmaceutical company's anticompetitive demands that infringe on the independent decision-making of providers and limit patient choice.' Novo Nordisk A/S (NYSE: NVO) is a Danish healthcare company operating globally. It develops, manufactures, and markets pharmaceutical products for the treatment of chronic diseases, primarily diabetes and obesity. Its well-known products include Ozempic, Wegovy, Rybelsus, and Norditropin. While we acknowledge the potential of NVO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
Health minister: Singapore to raise first-time blood donor age limit to 65 from 2026
SINGAPORE, June 29 — From January 1, 2026, the age limit for first-time blood donors in Singapore will be raised from 60 to 65, Health Minister Ong Ye Kung announced yesterday. According to Channel News Asia (CNA), Ong said the move aims to expand the donor pool amid rising demand and an ageing population. He also said the decision reflects longer life expectancy and data showing fewer adverse reactions among older donors. 'There is no reason to believe that once you cross 60 years old, suddenly the adverse reaction prevalence rate is going to shoot up,' he reportedly said at a World Blood Donor Day event yesterday. Singapore's new limit brings it in line with countries such as the United Kingdom and South Korea. Currently, only repeat donors can give blood beyond age 60, if they meet health criteria. The country's blood supply remains under pressure, with new donor numbers falling and demand increasing — over 35,000 patients required transfusions in 2023. Seasonal dips and past critical shortages, especially in Group O blood, have also posed challenges.
